The FDA said Neurochem Inc.'s Kiacta (eprodisate, formerly Fibrillex) is approvable for treating amyloid A (AA) amyloidosis, and the company's management is hopeful of clearing any final regulatory hurdles without additional trials. (BioWorld Today) Read More